贫血和铁缺乏症对心力衰竭的影响,其中排泄分数略有减少
Tobias Schupp1, Kathrin Weidner1, Marielen Reinhardt1
1Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
European journal of clinical investigation
|April 10, 2024
概括
贫血和铁缺乏症在心力衰竭中很常见,轻微减少射出分数 (HFmrEF),显著增加死亡率和住院治疗. 早期检测和管理对于改善患者的治疗结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 血液学 血液学 血液学
背景情况:
- 轻微减少喷射分数 (HFmrEF) 的心力衰竭是一个日益严重的临床问题.
- 在HFmrEF中,贫血和铁缺乏症的预后意义仍然不太清楚.
- 了解这些情况对于优化患者护理和结果至关重要.
研究的目的:
- 为了确定患有HFmrEF的患者中贫血和缺铁的患病率.
- 调查贫血和缺铁对HFmrEF患者预后的影响.
- 确定这些疾病与不良临床结果之间的关联.
主要方法:
- 从2016年到2022年连续的HFmrEF患者的回顾性分析.
- 基于标准血红蛋白值的贫血的定义 (男性<13 g/dL,女性<12 g/dL).
- 对贫血患者和非贫血患者,以及缺铁患者和非缺铁患者的结局进行比较,评估所有原因死亡率和30个月后与HF相关的再住院.
主要成果:
- 在2,154名HFmrEF患者中,有52%患有贫血,这与因任何原因死亡的风险增加了3倍,与HF相关的再住院的风险增加了2.3倍.
- 缺铁,虽然仅在27%的贫血患者中进行评估,但与高血压再入院的风险更高有关 (HR=1.746,p=.038).
- 贫血独立预测不良结果,即使在多变量调整后.
结论:
- 贫血和铁缺乏症在超过一半的HFmrEF患者中非常普遍.
- 这两种情况都独立地与更糟糕的长期预后有关,包括增加死亡率和重新住院.
- 这些发现强调了在HFmrEF中查和管理贫血和铁缺乏症的重要性.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577